Foundation News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.


Crohn’s & Colitis Foundation and Evotec Enter Agreement to Advance Drug Discovery for Novel IBD Therapies

he Crohn’s & Colitis Foundation has joined forces with life science company Evotec SE, to help advance drug discovery for two innovative drug targets stemming from cutting-edge academic research for inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis.

January 9, 2024

Mark Cuban Cost Plus Drugs

The Crohn’s & Colitis Foundation Joins Forces with the Mark Cuban Cost Plus Drug Company to Improve Medication Access for IBD Patients

The Crohn’s & Colitis Foundation, the nation’s leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD), is joining forces with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications.

October 3, 2023

Alan Moss

The Crohn’s & Colitis Foundation Appoints Alan Moss, MD, as Chief Scientific Officer

Alan Moss, MD, a renowned clinician-scientist, begins his tenure today as the Chief Scientific Officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the Director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and Professor of Medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.

September 25, 2023

Crohn’s & Colitis Foundation Statement on UnitedHealthcare Delaying New Prior Authorization Policy for GI Diagnostic Services

UnitedHealthcare (UHC) has delayed implementing a new policy that would have required prior authorization for most physician-prescribed endoscopy and colonoscopy procedures, which was slated to begin June 1. This decision comes after UHC faced significant backlash from the GI community, and a rally was led by the Crohn's & Colitis Foundation alongside IBD healthcare professionals and patients outside UHC’s Minnesota headquarters on May 31. The Foundation was invited to meet with UHC to discuss the policy after the rally.

June 5, 2023

Crohn’s & Colitis Foundation’s IBD Plexus Platform Confirms Findings on Need for Personalized Approach in Use of 5-ASA in Treating Inflammatory Bowel Disease

Using collective data made available by IBD Plexus, researchers’ findings advance the possibility of microbiome-based personalized medicine for IBD treatment.

May 30, 2023

Crohn’s & Colitis Foundation Applauds Senate HELP Committee for Including the Safe Step Act in PBM Reform Legislation

Legislation will give patients and their doctors a process to seek exception to Step Therapy requirements that may delay necessary care

May 16, 2023

Crohn’s & Colitis Foundation Urges Congress To Pass Legislation to Reform Pharmacy Benefit Manager (PBM) Industry

The Crohn's & Colitis Foundation advocates for reform in the Pharmacy Benefit Manager (PBM) industry due to the negative impact it has on patients' access to medicine.

May 1, 2023

Crohn’s & Colitis Foundation Makes Statement in Support of FDA’s Role in Safeguarding Patients

Last week, in an unprecedented decision, a Texas federal judge invalidated the Food and Drug Administration’s (FDA) approval of a drug that was approved by the agency in 2000.

April 12, 2023